Pcn15 Cost-Effectiveness of New Targeted Therapy Sunitinib Malate as Second Line Treatment in Metastatic Renal Cell Carcinoma in Argentina

Aiello, EC; Muszbek, N.; Richardet, Eduardo; Lingua, Alejo; Charbonneau, Claudie; Remak, Edit

doi:10.1016/s1098-3015(10)68926-7

Cited by 4 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(3) 20 (4) 14 ( (31) 6 (6) 1 (2) Ejection fraction decline (5) 16 (4) 13 (6) 12 (11) 7 (11) Other symptoms 6 (1) 6 ( (2) 3 (1) 8 (4) 3 (3) 2 ( (4) 11 (2) 18 (9 104,[128][129][130][131][132] . meeting.the.inclusion.criteria;.three 104,128,129 . reporting.on.sunitinib.versus.BSC.and.three [130][131][132] .…”

Section: Sites Of Metastases N (%)mentioning

confidence: 99%

Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation

Coon

Hoyle

Green

et al. 2010

Health Technol Assess

View full text Add to dashboard Cite

How to obtain copies of this and other HTA programme reports An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below).Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our despatch agents.Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per issue and for the rest of the world £3 per issue. How to order:-fax (with credit card details) -post (with credit card details or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you to either print out your order or download a blank order form. Contact details are as follows:Synergie UK (HTA Department) Digital House, The Loddon Centre Wade Road Basingstoke Hants RG24 8QW Email: orders@hta.ac.uk Tel: 0845 812 4000 -ask for 'HTA Payment Services' (out-of-hours answer-phone service) Fax: 0845 812 4001 -put 'HTA Order' on the fax header Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to University of Southampton and drawn on a bank with a UK address. Paying by credit cardYou can order using your credit card by phone, fax or post. SubscriptionsNHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for each volume (normally comprising 40-50 titles). The commercial subscription rate is £400 per volume (addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume. How do I get a copy of HTA on DVD?Please use the form on the HTA website (www.hta.ac.uk/htacd/index.shtml). HTA on DVD is currently free of charge worldwide.The website also provides information about the HTA programme and lists the membership of the various committees. HTA

show abstract

Section: Sites Of Metastases N (%)mentioning

confidence: 99%

Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation

Coon

Hoyle

Green

et al. 2010

Health Technol Assess

View full text Add to dashboard Cite

show abstract

“…NE: North East; NW: North West; SE: South East; SW: South West. Data taken from[14,[26][27][28][29]52].…”

mentioning

confidence: 99%

Cost–effectiveness of sunitinib in metastatic renal cell carcinoma

Purmonen¹

2011

Expert Review of Pharmacoeconomics & Outcomes Research

View full text Add to dashboard Cite

Sunitinib is one of the first targeted treatments for metastatic renal cell carcinoma (mRCC) and is currently considered as the standard of care for most of the mRCC patients in the first-line setting. The introduction of targeted treatments has, in the past few years, led to improvements in disease management and survival of these patients, however, with increasing cost. Cost-effectiveness of sunitinib has been assessed on several occasions and a systematic literature search was conducted to find all published research articles as well as all research abstracts presented in various congresses. This article presents an overview of the currently existing cost-effectiveness studies of sunitinib in mRCC, along with the main results and the utilized methodology. In most of the economic evaluations sunitinib has been deemed to be a cost-effective treatment option compared with other treatments.

show abstract

Economic Evaluations of Pharmaceuticals Granted a Marketing Authorisation Without the Results of Randomised Trials: A Systematic Review and Taxonomy

2016

View full text Add to dashboard Cite

(247 / 250) BackgroundPharmaceuticals are usually granted a marketing authorisation on the basis of randomised controlled trials (RCTs). Occasionally the efficacy of a treatment is assessed without a randomised comparator group (either active or placebo). ObjectiveTo identify and develop a taxonomic account of economic modelling approaches for pharmaceuticals licensed without randomised control trial data. MethodsWe searched PubMed, the websites of UK health technology assessment (HTA) bodies and the ISPOR Scientific Presentations Database for assessments of the 74 indications granted a marketing authorisation by the FDA or EMA from Jan-1999 to May-2014 without RCT data. The outcome of interest was the approach to modelling efficacy data. ResultsFifty-one unique models were identified based on 29 peer-reviewed articles, 30 health technology appraisals (HTAs), and 15 ISPOR abstracts concerning 30 indications (44 indications had not been modelled). Also notable was the low rate of submission to HTA agencies (28/98).The majority of models (43/51) were based on 'historical controls' -comparisons to previous meta-analysis or pooling of trials (5), individual trials (19), registries/case series (14), or expert opinion (7). Other approaches used the patient as their own control, performed threshold analysis, assumed time on treatment was added to overall survival, or performed cost-minimization. ConclusionsThere is considerable variation in the quality and approach of models constructed for drugs granted a marketing authorisation without a RCT. The most common approach is of a naïve comparisons to historical data (using other trials / registry data as a control group), with considerable scope for bias. Key points for decision makers When pharmaceuticals are licensed without comparative data, economic models are generally constructed using a historical control  Even within evaluations using the same method, the quality and appropriateness of an approach varies  The appropriateness of historical comparison for modelling using uncontrolled study data requires further methodological evaluation Article: Word count: 2261

show abstract

Pcn15 Cost-Effectiveness of New Targeted Therapy Sunitinib Malate as Second Line Treatment in Metastatic Renal Cell Carcinoma in Argentina

Cited by 4 publications

References 0 publications

Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation

Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation

Cost–effectiveness of sunitinib in metastatic renal cell carcinoma

Economic Evaluations of Pharmaceuticals Granted a Marketing Authorisation Without the Results of Randomised Trials: A Systematic Review and Taxonomy

Contact Info

Product

Resources

About